High-dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increase. Hellkvist L, Hjalmarsson E, Weinfeld D, Dahl A, et al. Allergy 2022;77:883-896.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hellkvist L, Hjalmarsson E, Weinfeld D, Dahl A, et al. High-dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increase. Allergy 2022;77:883-896.
PMID: 34379802